Adulterated and misbranded medications Compounded GLP-1RAs have been the subject of numerous lawsuits
Current clinical data indicate that GLP-1R agonists reduce BP in diabetic patients (98)
Some studies show that up to 40% of the weight loss observed in patients on semaglutide is attributable to loss of lean muscle mass, which is viewed as a major shortcoming
A patient with obesity and an increased risk profile may need closer monitoring than someone with a smaller amount of weight to lose, which can affect scheduling and cost
pulse generator only ), 93146 ( Interrogation device evaluation (in person), carotid sinus baroreflex activation therapy (BAT) modulation system including telemetric iterative communication with the implantable device to monitor device diagnostics and programmed therapy values, with interpretation and report (for example, battery status, lead impedance, pulse amplitude, pulse width, therapy frequency, pathway mode, burst mode, therapy start/stop times each day)
